Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. The maker of blockbuster weight-loss drugs reduced its 2025 guidance as alternative versions of its drugs weighed on demand.